Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 119

1.

Short communication: atazanavir-based therapy is associated with higher hepatitis C viral load in HIV type 1-infected subjects with untreated hepatitis C.

Rivero-Juarez A, Mira JA, Santos-Gil I, Lopez-Cortes LF, Girón-Gonzalez JA, Marquez M, Merino D, Tellez F, Caruz A, Pineda JA, Rivero A; Grupo Andaluz Para El Estudio de Las Hepatitis Víricas Hepavir de la Sociedad Andaluza de Enfermedades Infecciosas Saei.

AIDS Res Hum Retroviruses. 2013 Feb;29(2):223-5. doi: 10.1089/AID.2012.0126. Epub 2012 Oct 10.

2.

HCV RNA decline in chronic HCV genotype 2 and 3 during standard of care treatment according to IL28B polymorphism.

Stenkvist J, Sönnerborg A, Weiland O.

J Viral Hepat. 2013 Mar;20(3):193-9. doi: 10.1111/j.1365-2893.2012.01645.x. Epub 2012 Aug 21.

PMID:
23383658
3.

Association between the IL28B genotype and hepatitis C viral kinetics in the early days of treatment with pegylated interferon plus ribavirin in HIV/HCV co-infected patients with genotype 1 or 4.

Rivero-Juárez A, Camacho Espejo A, Perez-Camacho I, Neukam K, Caruz A, Mira JA, Mesa P, García-Lázaro M, Torre-Cisneros J, Pineda JA, Rivero A.

J Antimicrob Chemother. 2012 Jan;67(1):202-5. doi: 10.1093/jac/dkr439. Epub 2011 Oct 11.

PMID:
21990051
4.

Impact of HIV infection in patients infected with chronic HCV (genotypes 1a and 3a): virological and clinical changes.

Behzadpour D, Ahmadi Vasmehjani A, Mousavi Nasab SD, Ahmadi NA, Baharlou R.

Pathog Glob Health. 2016 Oct - Dec;110(7-8):310-315. Epub 2016 Nov 10.

5.

Influence of liver fibrosis stage on plasma levels of antiretroviral drugs in HIV-infected patients with chronic hepatitis C.

Barreiro P, Rodríguez-Novoa S, Labarga P, Ruiz A, Jiménez-Nácher I, Martín-Carbonero L, Gonzalez-Lahoz J, Soriano V.

J Infect Dis. 2007 Apr 1;195(7):973-9. Epub 2007 Feb 20.

PMID:
17330787
6.

Assessing the impact of substance use and hepatitis coinfection on atazanavir and lopinavir trough concentrations in HIV-infected patients during therapeutic drug monitoring.

Slish J, Ma Q, Zingman BS, Reichman RC, Fischl MA, Gripshover B, Forrest A, Brazeau D, Boston NS, Catanzaro L, DiFrancesco R, Morse GD.

Ther Drug Monit. 2007 Oct;29(5):560-5.

PMID:
17898644
7.

Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failures.

Johnson M, Grinsztejn B, Rodriguez C, Coco J, DeJesus E, Lazzarin A, Lichtenstein K, Rightmire A, Sankoh S, Wilber R.

AIDS. 2005 Apr 29;19(7):685-94.

PMID:
15821394
8.

Prediction of response to pegylated interferon plus ribavirin in HIV/hepatitis C virus (HCV)-coinfected patients using HCV genotype, IL28B variations, and HCV-RNA load.

Neukam K, Camacho A, Caruz A, Rallón N, Torres-Cornejo A, Rockstroh JK, Macías J, Rivero A, Benito JM, López-Cortés LF, Nattermann J, Gómez-Mateos J, Soriano V, Pineda JA.

J Hepatol. 2012 Apr;56(4):788-94. doi: 10.1016/j.jhep.2011.11.008. Epub 2011 Dec 13.

PMID:
22173157
9.

Factors associated with hepatitis C virus RNA levels in early chronic infection: the InC3 study.

Hajarizadeh B, Grady B, Page K, Kim AY, McGovern BH, Cox AL, Rice TM, Sacks-Davis R, Bruneau J, Morris M, Amin J, Schinkel J, Applegate T, Maher L, Hellard M, Lloyd AR, Prins M, Geskus RB, Dore GJ, Grebely J; InC3 Study Group.

J Viral Hepat. 2015 Sep;22(9):708-17. doi: 10.1111/jvh.12384. Epub 2015 Jan 8.

10.

Impact of the peginterferon-α 2a and ribavirin plasma levels on viral kinetics and sustained virological response in genotype 1 HCV/HIV-co-infected patients with the unfavourable non-CC IL28B genotypes.

Torres-Cornejo A, Ruiz-Valderas R, Jimenez-Jimenez L, Abad-Molina C, Gutierrez-Valencia A, Viciana P, Lopez-Cortes LF.

J Viral Hepat. 2014 Mar;21(3):178-88. doi: 10.1111/jvh.12128. Epub 2013 Jul 17.

PMID:
24438679
11.

Prediction of response to pegylated interferon plus ribavirin by IL28B gene variation in patients coinfected with HIV and hepatitis C virus.

Pineda JA, Caruz A, Rivero A, Neukam K, Salas I, Camacho A, Palomares JC, Mira JA, Martínez A, Roldán C, de la Torre J, Macías J.

Clin Infect Dis. 2010 Oct 1;51(7):788-95. doi: 10.1086/656235.

PMID:
20804372
12.

Association between IL28B gene polymorphisms and plasma HCV-RNA levels in HIV/HCV-co-infected patients.

Labarga P, Soriano V, Caruz A, Poveda E, Di Lello FA, Hernandez-Quero J, Moreno S, Bernal E, Miró JM, Leal M, Gutierrez F, Portilla J, Pineda JA; CoRIS.

AIDS. 2011 Mar 27;25(6):761-6. doi: 10.1097/QAD.0b013e32834488e7. Erratum in: AIDS. 2013 Jul 31;27(12):2001. Di Lello, Frederico [corrected to Di Lello, Federico A].

PMID:
21378537
13.

Liver injury and changes in hepatitis C Virus (HCV) RNA load associated with protease inhibitor-based antiretroviral therapy for treatment-naive HCV-HIV-coinfected patients: lopinavir-ritonavir versus nelfinavir.

Sherman KE, Shire NJ, Cernohous P, Rouster SD, Omachi JH, Brun S, Da Silva B.

Clin Infect Dis. 2005 Oct 15;41(8):1186-95. Epub 2005 Sep 13.

PMID:
16163639
14.

Spontaneous hepatitis C virus clearance in HIV patients with chronic hepatitis C bearing IL28B-CC alleles using antiretroviral therapy.

Vispo E, Barreiro P, Plaza Z, Fernández-Montero JV, Labarga P, de Mendoza C, Sierra-Enguita R, Treviño A, Lopez M, Soriano V.

AIDS. 2014 Jun 19;28(10):1473-8. doi: 10.1097/QAD.0000000000000275.

PMID:
24637541
15.

LDLr genotype modifies the impact of IL28B on HCV viral kinetics after the first weeks of treatment with PEG-IFN/RBV in HIV/HCV patients.

Rivero-Juarez A, Camacho A, Caruz A, Neukam K, Gonzalez R, Di Lello FA, Perez-Camacho I, Mesa P, Torre-Cisneros J, Peña J, Pineda JA, Rivero A.

AIDS. 2012 May 15;26(8):1009-15. doi: 10.1097/QAD.0b013e3283528b1c.

PMID:
22382144
16.

The IL28B effect on hepatitis C virus kinetics among HIV patients after the first weeks of pegylated-interferon/ribavirin treatment varies according to hepatitis C virus-1 subtype.

Rivero-Juarez A, Lopez-Cortes LF, Camacho A, Caruz A, Torres-Cornejo A, Martinez-Dueñas L, Ruiz-Valderas R, Torre-Cisneros J, Gutierrez-Valencia A, Rivero A.

AIDS. 2013 Jul 31;27(12):1941-7. doi: 10.1097/QAD.0b013e328360ea1e.

PMID:
23917425
17.

HIV-coinfection leads to a modest increase in plasma HCV-RNA load in patients with chronic HCV infection.

Neukam K, García-Rey S, Cifuentes C, Macías J, Mira JA, Vázquez MJ, Parra-Sánchez M, Palomares JC, Merchante N, Di Lello FA, Pineda JA.

Antiviral Res. 2012 Sep;95(3):212-5. doi: 10.1016/j.antiviral.2012.06.009. Epub 2012 Jun 29.

PMID:
22750672
18.

Predicted effect of direct acting antivirals in the current HIV-HCV-coinfected population in Spain.

Poveda E, Vispo E, Barreiro P, de Mendoza C, Labarga P, Fernández-Montero JV, Martin-Carbonero L, Soriano V.

Antivir Ther. 2012;17(3):571-5. doi: 10.3851/IMP1992. Epub 2011 Dec 15.

PMID:
22293607
19.

Hepatic steatosis in HIV-HCV coinfected patients receiving antiretroviral therapy is associated with HCV-related factors but not antiretrovirals.

Martinez V, Ta TD, Mokhtari Z, Guiguet M, Miailhes P, Valantin MA, Charlotte F, Bertheau P, Molina JM, Katlama C, Caumes E.

BMC Res Notes. 2012 Jul 9;5:180. doi: 10.1186/1756-0500-5-180.

20.

Interleukin-28b CC genotype predicts early treatment response and CT/TT genotypes predicts non-response in patients infected with HCV genotype 3.

Gupta AC, Trehanpati N, Sukriti S, Hissar S, Midha V, Sood A, Sarin SK.

J Med Virol. 2014 Apr;86(4):707-12. doi: 10.1002/jmv.23876. Epub 2014 Jan 10.

PMID:
24415442

Supplemental Content

Support Center